DAK Gesundheit Tender

Contract notice: Conclusion of a non-exclusive discount agreement in accordance with ⧠130a para. Interferon beta-1a (only for dafo for intramuscular injection, Atc l03ab07, Fd time 1.5.2021-30.4.2023 DAK-Gesundheit assumes that this procedure does not fall within the scope of antitrust law due to the lack of a selection decision and therefore the non-discriminatory accessibility of all pharmaceutical companies. Regardless of this, it ends automatically with the entry into force of the exclusive contract for interferon beta-1a (exclusively for Dafo for intramuscular injection), ATC L03AB07, as a result of a formal award procedure according to the regulations of Part 4 of the GWB with one or more Contractual partners. In order to do justice to the diversity of potential contractual partners within the framework of the approval model, every pharmaceutical company is able to conclude a framework agreement at any time and under the same conditions during the term of the contract. The contract documents required for this are available for download from the online portal www.dtvp.de/center under the link given under I.3). The prerequisites for the conclusion or the subsequent joining of the contracts that will come into force for the first time on May 1st, 2021 is the complete and timely submission of the following documents (available for download under I.3) ) to the following department at DAK-Gesundheit: 1. Letter of offer, 2. Recognition of the contractual requirements of DAK-Gesundheit, in particular the given discounts, by submitting the contract with the name or company stamp by the interested party at the designated point, 3. The completed annexes 1 and 2 to the contract. The interested party has to enter the drugs for the above-mentioned active substance, which are to be the subject of the contract. The documents must be submitted by email to: openhouse@dak.de DAK health Pharmaceuticals department (0032 00) Nagelsweg 27-31 20097 Hamburg Attachment 2 is expressly to be sent as an Excel file to the e-mail address openhouse@dak.de . Contracts within the scope of this model and the above-mentioned active ingredient will be concluded for the first time with effect from May 1, 2021 and will end on April 30, 2023. Interested parties who want to become a contractual partner on this date must submit the above-mentioned documents by e-mail by the 5th of the previous month. The offer must be submitted in text form as an electronic offer by email to openhouse@dak.de . The submission of the offer by post is not provided for in this procedure. Please do not submit the offer via the German procurement portal. Electronic receipt of the complete documents by email to the email address openhouse@dak.de is sufficient to meet the deadline . Later joinings are possible at any time. In order to be able to join during the term of the contract on the 1st or 15th of